ENINGIOMAS are common brain tumors, accounting for ~ 25% of all primary intracranial neoplasias. 38 Many meningiomas are benign (WHO Grade I), but up to 20% of all meningiomas are assigned to the WHO Grades II (atypical) and III (anaplastic/malignant meningiomas). Overall survival of patients with meningioma is surprisingly poor. In a large population-based series of Ͼ 9000 patients, the 5-year survival rate was only 69%. 30, 44 Most meningiomas are sporadic tumors of unknown etiology. Cranial irradiation (for example, for tinea capitis 35 and NF2) are the only well-known risk factors for the development of meningiomas. Somatic mutations of the NF2 gene, which is located on the long arm of chromosome 22 (22q12), and LOH for markers from 22q represent the most frequent genetic alterations and are found in up to 60% of sporadic meningiomas of all grades. Alterations in the NF2 gene and 22q LOH are thought to be early events in meningioma tumorigenesis. 34 Deletions of 1p, 9p, 10q, and 14q have been associated with malignant progression. The actual (tumor suppressor) genes targeted by these deletions have not been identified yet with the possible exception of INK4a on 9p. 13, 34 Tumor suppressor gene inactivation can also result from epigenetic changes such as DNA (CpG island) methylation. Hypermethylation of the promoter region of genes can abolish transcription ("gene silencing"). 4, 15, 19 Promoter hypermethylation plays an important role in the formation of various tumors, including meningiomas. In many cancers, epigenetic silencing through promoter methylation may occur as frequently as mutations of tumor suppressor genes. 3, 16, 19, 27, 31 S-adenosylmethionine is an important metabolite of methionine metabolism and a universal methyl group donor for methylation reactions, including DNA methylation. Object. Functionally relevant polymorphisms of methionine and folate metabolism have been shown to be associated with various human cancer entities including cerebral lymphoma and glioblastoma multiforme. The authors investigated the association of 7 functional polymorphisms of methionine metabolism with meningioma formation.
Functional polymorphisms of methionine pathways have been found to be associated with a wide variety of tumors, including colorectal cancer, 28, 42 cervical intraepithelial neoplasia, 14 acute lymphoblastic leukemia and systemic nonHodgkin lymphoma, 12, 22, 37 breast cancer, 26 and 2 intracranial cancers: glioblastoma multiforme 36 and primary intracranial lymphoma. 25 In the present study we investigated 7 functional polymorphisms of methionine metabolism for an association with meningioma formation.
Materials and Methods
We investigated genotype in 290 patients with meningioma (28% male; mean age Ϯ standard deviation 59.2 Ϯ 13.9 years) and 287 age-and sex-matched controls (28% male; mean age 52.9 Ϯ 15.7 years). The patients with meningioma were of Caucasian origin and had been recruited between 1996 and 2005 by the tumor bank of the University Hospital of Bonn Department of Neurosurgery, a tertiary referral center serving a population of ~ 1,000,000 in the greater Bonn area. The control group consisted of Bonn area residents of Caucasian origin who had no history of cancer. They were recruited from a pool of apparently healthy relatives of stroke patients referred to the University Hospital of Bonn Department of Neurology for screening for cerebrovascular disease risk factors.
All histological diagnoses were made at the Institute for Neuropathology/German Brain Tumor Reference Center at the University of Bonn. In 82 patients the tumor was WHO Grade II, in 18 patients WHO Grade III, and in all others WHO Grade I.
Genotyping for 7 functional polymorphisms of homocysteine metabolism was performed. The polymorphisms were as follows: DHFR c.594ϩ59del19 (supposed to affect transcription levels), MTHFR c.677C Ͼ T (leading to the amino acid exchange A222V in the MTHFR peptide), MTHFR c.1298A Ͼ C (amino acid exchange E429A), MTR c.2756A Ͼ G (amino acid exchange D919G), RFC1 c.80G Ͼ A (amino acid exchange R27H), CBS 844_855ins68 (splice alteration), and Tc2 c.776C Ͼ G (amino acid exchange P259R). Genomic DNA prepared from peripheral leukocytes was used for genotyping by polymerase chain reaction amplification and restriction analysis as previously published. 1, 25, 45 Deviations from Hardy-Weinberg equilibrium were analyzed using a chi-square goodness-of-fit test between observed and expected numbers for both patient and control groups and each genetic variant separately (␣ = 0.05).
As a primary statistical analysis, we calculated the chi-square test values for the Pearson chi-square test for all 3 allelotypes of each polymorphism (2 df) for the differences between patients and controls. Due to multiple testing (7 polymorphisms), the threshold for statistical significance was restrictively defined as 0.007 (Bonferroni correction). In addition, multiple nominal regression analysis was performed with simultaneous analysis of all 7 polymorphisms and age and sex as covariables.
The study was approved by the local ethics committee. All participants gave informed written consent.
Results
The results of genotyping are shown in Table 1 . The distribution of the Tc2 c.776C Ͼ G genotypes of the controls deviated significantly from the Hardy-Weinberg equilibrium. Therefore, the data for the Tc2 variant were excluded from further analysis. No further significant deviations from the Hardy-Weinberg equilibrium were observed.
The variant CBS c.844_855ins68-that is, the allele carrying the insertion ("ins" or "i") as opposed to the wildtype allele designated as deletion ("del" or "d")-was significantly overrepresented in the 290 patients with WHO Grade I-III meningioma (patients: dd/id/ii, 0.81/0.18/0.01; controls: dd/id/ii, 0.88/0.12/0.00; 2 df, chi-square 6.51, p = 0.039; OR [1 df] 1.66, 95% CI 1.04-2.65; Table 1 ). Multiple nominal regression analysis confirmed that the variant CBS c.844_855ins68 independently predicted meningioma formation in our study sample (covariables: age, sex; chi-square 8.97; p = 0.011). The frequency of the CBS c.844_855ins68 allele in the control group was very similar to the frequencies reported for a large German control population 24 and an Australian population. 43 We also observed an association of the DHFR c.594+59del19 variant with meningioma formation in the overall sample (Pearson chisquare 6.06, p = 0.048), but this association was no longer significant after correction for multiple testing, nor in the multivariate analysis (chi-square 3.18, p = 0.204). There was no significant effect of the other 5 polymorphisms.
Explorative Table 2 ).
Discussion
We analyzed 7 functional polymorphisms of methionine metabolism in 290 patients with meningioma and 287 controls. The mutant ins allele CBS c.844_855ins68 was found to be overrepresented in patients with meningioma, suggesting that this variant is associated with meningioma formation of any WHO grade. The OR of 1.66 (95% CI 1.04-2.65) suggests that carriers of the mutant CBS c.844_ 855ins68 have a moderately increased risk of meningioma. In addition, the G allele of MTR c.2756A Ͼ G was significantly underrepresented among patients with anaplastic/ malignant meningiomas, suggesting that it may protect against the formation of this meningioma subtype.
The available information on the biochemical consequences of these 2 genetic variants is limited and in part controversial. Cystathionine beta-synthase irreversibly removes homocysteine from the methionine cycle by transsulfuration of homocysteine to cystathionine (Fig. 1) . The polymorphic insertion c.844_845ins68 represents an imperfect duplication of the 3Ј splice site at the CBS intron7-exon8 junction and generates a second 3Ј splice site, leading to changes of the intranuclear CBS transcript processing and yielding a suggested gain of CBS function. 39 Carriers of the insertion CBS c.844_855ins68 exhibit higher fasting SAM blood levels and higher post-methionineload ratios of blood SAM to blood SAH and of plasma total cysteine to plasma homocysteine compared with wild-type homozygotes, 18 suggesting increased SAM availability as well as higher CBS activity. Higher levels of SAM may lead to increased SAM-dependent DNA methylation. 8, 9 It has been shown that aberrant CpG island methylation of cancer-related genes in meningiomas is relatively frequent. 3, 27 In summary, the CBS c.844_855ins68 polymorphism could possibly promote epigenetic silencing of tumor suppressor genes by promoter hypermethylation in meningiomas through an increased availability of SAM. This might provide an explanation for our finding of an association between this genetic variant and meningioma incidence. ( with simultaneous analysis of all 7 polymorphisms together with age and sex as covariables) for the differences between patients and controls. Under each genetic variant, it also shows the percentage of controls and patients who were homozygous carriers of the wild type allele (for example, CC)-that is, those in whom the single nucleotide polymorphism (SNP) is absent, heterozygous carriers of the SNP (for example, CT), and homozygous carriers of the SNP (for example, TT). Due to technical reasons, some allelotypes could not be determined conclusively. Such cases were excluded from the statistical analysis as noted.
† Data from 1 patient were excluded from the analysis. ‡ Data from 2 patients were excluded from the analysis. § Data from 1 control and 3 patients were excluded from the analysis. The rarity of WHO Grade III meningiomas only allowed for analysis of a limited sample. Nevertheless, we observed a potentially sizable protective effect (OR 18.55, 95% CI 1.11-311.46) of the G allele of MTR c.2756A Ͼ G against the development of anaplastic/malignant meningiomas. These data are in line with the results of former studies showing that the G allele of MTR c.2756A Ͼ G reduces susceptibility to a number of other malignant tumors, such as colorectal cancer, 28, 42 breast cancer, 26 acute lymphoblastic leukemia and systemic non-Hodgkin lymphoma, 12, 22 primary central nervous system non-Hodgkin lymphoma, 25 and glioblastoma multiforme. 36 The functional consequences of the missense variant MTR c.2756A Ͼ G with respect to MTR expression and activity have not been studied in detail yet, but it is known that MTR catalyzes the remethylation of homocysteine to methionine and it is therefore involved in methyl group, folate, and nucleic acid metabolism. 25 Impairment of these pathways can lead to uracil misincorporation into DNA, aberrant DNA methylation, inefficient DNA repair, and increased chromosome malsegregation and chromosomal breakage. In other words, it can result in genetic instability and increased mutation rates. 2 Hypermethylation of CpG islands and consecutive silencing of tumor suppressor genes may be less frequent in tumors occurring in carriers of the MTR c.2756G allele, which might explain this variant's protective effect against several malignancies.
33 Accordingly, in a family-based study, we verified that the G allele is associated with lower global CpG methylation in genomic DNA (unpublished data), and observed that the presence of the G allele promotes disease-free longevity in the German population. 23 The frequency of the G allele of MTR c.2756A Ͼ G in the control group was very similar to the previously reported frequency of this allele in German 24 and other populations.
12,41
Methionine metabolism is not only influenced by functional polymorphisms but also by the availability of vitamins. 11, 32 The activity of MTR depends on folate and vitamin B12 levels, and CBS activity depends on vitamin B6. 32 These findings might link nutritional factors to the incidence of meningiomas and other tumors. The data available on a possible association between folic acid intake and cancer formation are controversial, however. Although an inverse relationship between cancer risk and folate intake, DNA methylation, and DNA integrity has been demonstrated by some investigators, 6, 17, 21 others have speculated about a cancer-promoting effect of folic acid supplementation, 20, 29 and a large trial investigating folic acid intake and FIG. 1. Homocysteine metabolism. The amino acid methionine is activated to SAM, which is a ubiquitous methyl group donor. The degradation product of SAM is SAH, which is hydrolyzed to homocysteine. Homocysteine can be remethylated to methionine and SAM via MTR, which depends on derivatives of folate and vitamin B12 as cofactors. A lack of these vitamins is a common cause of impaired methionine metabolism presenting as hyperhomocysteinemia. The folate derivative is synthesized by MTHFR and DHFR, and the derivative of vitamin B12 is transported by Tc2. Alternatively, homocysteine can be transsulfurated by vitamin B6-dependent CBS and cystathionine gamma-lyase (CGL) to cysteine as a component of glutathione, which is important for the cellular redox system. Due to the existence of several functional variants in the genes involved in homocysteine metabolism and due to differences in dietary vitamin and amino acid uptake, homocysteine metabolism might vary considerably between individuals. ATP = adenosine triphosphate; FAD = flavin adenine dinucleotide; MAT = methionine adenosyltransferase; NADPH = nicotinamide adenine dinucleotide phosphate; SAHH = SAH hydrolase.
incidence of colorectal adenomas failed to show a beneficial effect. 7 To the best of our knowledge this is the first report of an association between genetic polymorphisms of methionine metabolism and meningiomas. With the exception of a report about an increased frequency of the CBS c.844_ 855ins68 polymorphism in a small case series involving children with Down syndrome and acute myeloid leukemia, 10 this is the first description of an association of this polymorphism with any human cancer. We are aware of the limitations imposed by the case-control design. Our findings should be retested in an independent case series.
Conclusions
Polymorphisms of methionine metabolism might play a role in meningioma formation. The impact of methionine metabolism on DNA methylation could be the underlying mechanism. As the individual kinetics of methionine metabolism are not only influenced by genetic variants but also by vitamin intake, dietary conditions might also contribute to meningioma incidence. Additional studies are warranted to retest the observed associations in independent patient samples. If confirmed, the causative character of this association as well as possible interactions with nutrition should be explored. Eventually, this may not only offer new insights into the mechanisms of meningioma formation and malignant progression, but may also suggest novel approaches to preventive strategies.
